Impact of Fkbp5 × Early Life Adversity × Sex in Humanized Mice on Multidimensional Stress Responses and Circadian Rhythmicity

Autor: Peleh T, Koros E, Blasius A, Kelly A. Allers, Nold, Portenhauser M, Del Prete D, Harris I, Michal Slezak, Bastian Hengerer, Iris-Tatjana Kolassa

The cumulative load of genetic predisposition, early life adversity (ELA) and lifestyle shapes the prevalence of psychiatric disorders. Single nucleotide polymorphisms (SNPs) in the human FKBP5 gene were shown to modulate disease risk. To enable inve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::670bdcba23ef22912718bab87e418a27
https://doi.org/10.1101/2021.07.06.450863

Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions.

Autor: Münster A; Systems Neurobiology Research Unit, University of Stuttgart, Stuttgart, Germany., Sommer S; Systems Neurobiology Research Unit, University of Stuttgart, Stuttgart, Germany., Kúkeľová D; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich (PUK) and University of Zurich (UZH), Zurich, Switzerland., Sigrist H; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich (PUK) and University of Zurich (UZH), Zurich, Switzerland., Koros E; CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Deiana S; CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Klinder K; Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Baader-Pagler T; Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Mayer-Wrangowski S; Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Ferger B; CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany; Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Bretschneider T; Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Pryce CR; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich (PUK) and University of Zurich (UZH), Zurich, Switzerland; Neuroscience Center Zurich, Zurich, Switzerland., Hauber W; Systems Neurobiology Research Unit, University of Stuttgart, Stuttgart, Germany., von Heimendahl M; CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Electronic address: moritz.von_heimendahl@boehringer-ingelheim.com.

Publikováno v: Neuropharmacology [Neuropharmacology] 2022 Aug 01; Vol. 213, pp. 109078. Date of Electronic Publication: 2022 May 10.

Determining the sweet detection threshold of COVID-19 patients during infection and recovery periods.

Autor: Alsanei, Woroud¹ (AUTHOR) walsanei@kau.edu.sa, Alhussin, Esraa² (AUTHOR), Natto, Zuhair S.³ (AUTHOR), Afeef, Marwah⁴ (AUTHOR), Aktar, Tugba⁵ (AUTHOR) tugba.aktar@alanya.edu.tr

Publikováno v: PLoS ONE. 8/29/2024, Vol. 19 Issue 8, p1-11. 11p.

The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.

Autor: Rosenbrock H; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.) holger.rosenbrock@boehringer-ingelheim.com., Giovannini R; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Schänzle G; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Koros E; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Runge F; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Fuchs H; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Marti A; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Reymann KG; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Schröder UH; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Fedele E; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.)., Dorner-Ciossek C; Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany (H.R., R.G., G.S., E.K., F.R., H.F., A.M., C.D.-C.); Leibniz Institute for Neurobiology, Magdeburg, Germany (K.G.R., U.H.S.); and Department of Pharmacy, Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy (E.F.).

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2019 Dec; Vol. 371 (3), pp. 633-641. Date of Electronic Publication: 2019 Oct 02.

Sodium Bicarbonate Decreases Alcohol Consumption in Mice.

Autor: Lin, Jason¹ (AUTHOR) jasonlin7710@gmail.com, Rivadeneira, Ana P.¹ (AUTHOR), Ye, Yani¹ (AUTHOR), Ryu, Clara¹ (AUTHOR), Parvin, Shangrila¹ (AUTHOR), Jang, Kyeongran¹ (AUTHOR), Garraway, Sandra M.¹ (AUTHOR), Choi, Inyeong¹ (AUTHOR) ichoi@emory.edu

Publikováno v: International Journal of Molecular Sciences. May2024, Vol. 25 Issue 9, p5006. 14p.